Labiotech.Eu company information, Employees & Contact Information

The 2025 AI biotech deals every executive should watch Labiotech.eu

The ESMO 2025 digest: Is oncology in good shape? Labiotech.eu

PCSK9’s second act: From antibodies to gene editing Labiotech.eu

These 18 french biotech startups could shape tomorrow’s medicine Labiotech.eu

Six companies leading the mRNA revolution in biotechnology Labiotech.eu

The advent of AI for peptide design: An emerging field Labiotech.eu

Five biotech companies making waves in Luxembourg Labiotech.eu

Prader Willi syndrome: five much-anticipated therapies poised for approval Labiotech.eu

Sweden’s biotech scene: what we learned at NLS Days 2025 Labiotech.eu

Five latest advancements in Tourette’s syndrome research Labiotech.eu

Can biotechnology reduce animal testing in medicine? Labiotech.eu

13 anti-aging biotech companies leading longevity in 2025 Labiotech.eu

Meet 7 promising Belgian biotech companies set to make waves in 2025 Labiotech.eu

Who inked the top biotech deals in July 2025? Labiotech.eu

Cambridge’s biotech scene: The cornerstone of the UK’s Golden Triangle Labiotech.eu

NATO invests in biotech: what's got the military alliance interested? Labiotech.eu

Beyond CRISPR: Brink Therapeutics raises $4 million with engineered recombinases Labiotech.eu

Nine tips to succeed in pharma-biotech partnerships Labiotech.eu

Partnering in action at BIOSPAIN: How partnering conferences fuel biotech innovation Labiotech.eu

How to solve the biotech bottleneck by funding ideas, not data Labiotech.eu

Radiopharma’s new wave: Nuclidium and Actithera raise the stakes Labiotech.eu

CRISPR technology’s next wave: Ten companies to watch in 2025 Labiotech.eu

ExCellThera’s first-in-class UM171 cell therapy is now approved in Europe Labiotech.eu

12 AI drug discovery companies you need to watch in 2025 Labiotech.eu

Eight biotech career paths where demand is skyrocketing Labiotech.eu

The biggest biotech funding rounds in August 2025 Labiotech.eu

10 promising biotech companies in Denmark that should be on your radar Labiotech.eu

Finland’s biotech stars: 9 names you will want to remember Labiotech.eu

5 South Korean biotech companies making global waves Labiotech.eu

12 ways biotechnology makes the world more sustainable Labiotech.eu

Biotech in Europe: what are the trends to watch out for? Labiotech.eu

The future of NSCLC treatment: what’s in store for the therapeutic space? Labiotech.eu

Watch these 9 small molecule drug discovery companies in 2025 Labiotech.eu

Boston’s biotech scene is booming: meet 14 biotech companies to watch in 2025 Labiotech.eu

Seven diseases that CRISPR technology could cure Labiotech.eu

What’s next for sickle cell disease? Key drugs to watch in 2025 Labiotech.eu

Six kidney disease companies you should know about in 2025 Labiotech.eu

Did Novo open the Canadian market to GLP-1 generics? Labiotech.eu

10 oncology deals in 2025 spotlight where industry leaders are betting big Labiotech.eu

10 biotech companies in China you should know about Labiotech.eu

2025 predictions: Which trends are set to shape the biotech industry this year? Labiotech.eu

ASCO 2025: what went down this week? Labiotech.eu

Organoids in cancer research: Paving the way for faster drug development across cancer indications Labiotech.eu

The hottest cancer vaccine companies you should know about Labiotech.eu

Is space the new frontier for biotech? Exobiosphere lands €2M to accelerate drug discovery beyond Earth Labiotech.eu

Unlocking the secrets of Basel's biotech boom: What drives the region's success Labiotech.eu

Biotech stars of 2024, did they shine or fade in 2025? Labiotech.eu

The AI race in biotech: Is Europe falling behind the US and China? Labiotech.eu

Biotech in Vienna: a place for growth and innovation? Labiotech.eu

Trade war: how new U.S. tariffs will impact the biopharma industry Labiotech.eu

Germany’s biotech stars: 14 companies to watch Labiotech.eu

Which biotech companies are gaining traction in genetic diseases? Labiotech.eu

The Netherlands: A strategic gateway for biotech clinical trials Labiotech.eu

Tapping into the regulatory goldmine: Interview with Ruxandra Teslo Labiotech.eu

mRNA vaccine funding cuts: the impact on U.S. healthcare and biotech Labiotech.eu

Seven lung cancer companies advancing new treatments in 2025 Labiotech.eu

Zombie biotechs and the mission to make them disappear fast Labiotech.eu

Fusion proteins set new trends in biotech with rising funding and deals Labiotech.eu

10 biotech companies to watch in 2025 Labiotech.eu

Psychedelics sans side effects: neuroplastogens gain ground Labiotech.eu

Oncolytic virus therapy for cancer: what’s been going on in 2025? Labiotech.eu

New treatments for high cholesterol: What should you watch now? Labiotech.eu

Sanofi pipeline shines with multiple deals and clinical progress Labiotech.eu

Meet 10 biotech companies you can’t miss in Spain in 2025 Labiotech.eu

Seattle top biotechs 2025: the 9 companies you should now about Labiotech.eu

The AI boom in cancer: Game-changer or just hype? Labiotech.eu

The future of diabetes treatment: Is a cure possible? Labiotech.eu

What’s next for narcolepsy? Exciting new drugs on the horizon Labiotech.eu

These biotech startups could change how we treat hepatitis B Labiotech.eu

Biotech in London: A thriving hub at the heart of the Golden Triangle Labiotech.eu

Stem cell therapy gains momentum in hearing loss care Labiotech.eu

2025 biotech funding tracker: recent highlights Labiotech.eu

The Netherlands Is emerging as biotech’s next global superpower Labiotech.eu

Gene therapy for cystic fibrosis gains clinical momentum Labiotech.eu

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology Labiotech.eu

AI’s bold mission: Bringing failed drugs back to life Labiotech.eu

Eight areas where gene therapy shines Labiotech.eu

Top biotech deals of February 2025 Labiotech.eu

Advancements in antimalarial drug discovery and development Labiotech.eu

CRISPR: The gene editing tool changing the world (2025 update) Labiotech.eu

How are biotechs tackling malaria? Labiotech.eu

Are royalty deals moving up the biopharma funding ladder? Labiotech.eu

Six psychedelic drug companies aiming to revolutionize mental health treatment Labiotech.eu

Serial acquirer Concentra Biosciences on a buyout spree in 2025 Labiotech.eu

Expert tips to choose the right CDMO for your biotech company Labiotech.eu

Pharma giants pull back on AAV research: what’s next for the gene therapy space? Labiotech.eu

From walls to insulation, nature-grown materials are reshaping how we build. Labiotech.eu

Can AI cure Alzheimer’s disease? Labiotech.eu

Saudi Arabia: is the country set to become a global biotech hub? Labiotech.eu

The biggest biotech funding rounds in March 2025 Labiotech.eu

The future of organ transplants: Xenotransplantation, 3D bioprinting and stem cells Labiotech.eu

From undruggable to oral therapy: The rise of STAT6 degraders Labiotech.eu

Injecting hope into skin cancer treatment: The promise of melanoma vaccines Labiotech.eu

Cell Therapy Industry Report 2022 Labiotech.eu

2025 biotech deals tracker: the latest partnerships and M&A activities Labiotech.eu

Six biotech companies leading the charge in hemophilia treatment Labiotech.eu

Biotech in 2024: A retrospective Labiotech.eu

The 7 hottest biotech companies in Taiwan Labiotech.eu

Biotech’s legal storm: Why securities class action lawsuits are surging Labiotech.eu

New non-opioid pain medication: How is the biotech industry fighting pain after the opioid crisis? Labiotech.eu